Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to-head clinical trials

National Psoriasis Foundation (NPF) defined treatment targets at week 12, with target response as BSA ≤1% and acceptable response as BSA ≤3% or BSA improvement from baseline ≥75% (1). Here, data were analyzed from head-to-head trials comparing ixekizumab vs. guselkumab, ustekinumab, and etanercept, to determine achievement of NPF treatment targets at week 12. This post hoc analysis included ixekizumab trials: IXORA-R, IXORA-S, integrated UNCOVER-2-3. At week 12, we assessed NPF treatment targets in the overall population, and biologic-experienced and -naïve subpopulations. Observed and NRI data (for treatment comparison with Fisher’s Exact test) are presented. Baseline demographics and disease characteristics were similar among treatment groups across the analyzed trials. At week 12, proportions (observed data, 95% CI) of patients treated with ixekizumab who achieved target and acceptable responses were, respectively: 65.6% (61.4-69.9) and 87.6% (84.6-90.5) in IXORA-R, 52.3% (43.8-60.8) and 84.1% (77.9-90.3) in IXORA-S, 54.2% (50.5-57.8) and 76.4% (73.3-79.6) in UNCOVER-2-3. At week 12, significantly (p<0.001) higher proportion (NRI data) of patients treated with ixekizumab achieved target and acceptable responses, respectively, compared to patients treated with guselkumab (61.0% vs. 44.8% and 81.3% vs. 70.6%, IXORA-R), ustekinumab (50.7% vs. 24.1% and 81.6% vs. 52.4%, IXORA-S), and etanercept (52.2% vs. 14.9% and 73.6% vs. 35.7%, UNCOVER-2-3). Biologic-experienced and -naïve patients treated with ixekizumab showed target and acceptable responses comparable to the overall ixekizumab population. At week 12, significantly higher proportions of patients treated with ixekizumab achieved NPF treatment targets vs. guselkumab, ustekinumab, or etanercept. Findings were consistent across the analyzed trials and subpopulations.